📊 DTIL Key Takeaways
Is Precision Biosciences Inc. (DTIL) a Good Investment?
Precision Biosciences is in severe financial distress with massive operating losses (-$52.1M), negative free cash flow (-$65.9M), and collapsing revenue (-50.1% YoY). Despite strong liquidity reserves ($110.8M cash), the company is burning cash at an unsustainable rate with no clear path to profitability, indicating a pre-revenue or failed clinical program status typical of troubled biotech firms.
Precision BioSciences shows weak core fundamentals, with revenue down 50.1% year over year, deeply negative operating and net margins, and substantial free cash flow burn. The balance sheet is currently supported by a large cash position, strong liquidity, and modest leverage, but the company’s cash runway is limited if operating losses and cash outflows persist. Growth quality appears low at this stage because declining revenue is being paired with heavy losses rather than improving operating efficiency.
Why Buy Precision Biosciences Inc. Stock? DTIL Key Strengths
- Substantial cash reserves of $110.8M provide 12-18 months of runway at current burn rates
- Strong liquidity position with 13.32x current ratio reduces near-term bankruptcy risk
- Low leverage with 0.24x debt-to-equity ratio limits debt servicing burden
- Strong liquidity with $110.82M in cash and current ratio of 13.32x
- Low balance sheet leverage with debt-to-equity of 0.24x
- Positive equity base of $92.25M provides some financial flexibility
DTIL Stock Risks: Precision Biosciences Inc. Investment Risks
- Catastrophic revenue collapse of 50.1% YoY indicates loss of major contracts or failed product commercialization
- Operating losses of $52.1M with negative margins of -152.2% demonstrate the business model cannot generate positive unit economics
- Cash burn rate of $65.8M annually will deplete reserves in approximately 20 months without additional financing or operational turnaround
- Negative ROE of -49.6% and ROA of -29.6% show shareholder capital is being destroyed at an accelerating rate
- Revenue declined 50.1% year over year, indicating weak top-line momentum
- Operating margin of -152.2% and net margin of -133.4% reflect an unsustainable profitability profile
- Operating cash outflow of $65.84M versus $110.82M cash suggests meaningful funding risk if burn continues
Key Metrics to Watch
- Quarterly operating cash flow burn rate and timeline to cash depletion
- Revenue stabilization or recovery in next two quarters; sustained decline signals terminal decline
- Progress on pipeline programs and clinical trial milestones; lack of catalysts increases dilution risk
- Quarterly cash burn relative to cash and equivalents
- Revenue stability and progress toward narrower operating losses
Precision Biosciences Inc. (DTIL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.32x current ratio provides a solid financial cushion.
DTIL Profit Margin, ROE & Profitability Analysis
DTIL vs Healthcare Sector: How Precision Biosciences Inc. Compares
How Precision Biosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Precision Biosciences Inc. Stock Overvalued? DTIL Valuation Analysis 2026
Based on fundamental analysis, Precision Biosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Precision Biosciences Inc. Balance Sheet: DTIL Debt, Cash & Liquidity
DTIL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Precision Biosciences Inc.'s revenue has declined by 41% over the 5-year period, indicating business contraction. The most recent EPS of $1.04 reflects profitable operations.
DTIL Revenue Growth, EPS Growth & YoY Performance
DTIL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $13.0K | $8.6M | $-1.84 |
| Q2 2025 | $18.0K | $8.6M | $-2.13 |
| Q1 2025 | $29.0K | $8.6M | $1.70 |
| Q3 2024 | $576.0K | -$8.1M | $-2.10 |
| Q2 2024 | $19.8M | $8.6M | $-3.13 |
| Q1 2024 | $8.8M | $8.6M | $1.70 |
| Q3 2023 | $7.4M | -$8.1M | $-0.07 |
| Q2 2023 | $3.8M | -$11.9M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Precision Biosciences Inc. Dividends, Buybacks & Capital Allocation
DTIL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Precision Biosciences Inc. (CIK: 0001357874)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DTIL
What is the AI rating for DTIL?
Precision Biosciences Inc. (DTIL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DTIL's key strengths?
Claude: Substantial cash reserves of $110.8M provide 12-18 months of runway at current burn rates. Strong liquidity position with 13.32x current ratio reduces near-term bankruptcy risk. ChatGPT: Strong liquidity with $110.82M in cash and current ratio of 13.32x. Low balance sheet leverage with debt-to-equity of 0.24x.
What are the risks of investing in DTIL?
Claude: Catastrophic revenue collapse of 50.1% YoY indicates loss of major contracts or failed product commercialization. Operating losses of $52.1M with negative margins of -152.2% demonstrate the business model cannot generate positive unit economics. ChatGPT: Revenue declined 50.1% year over year, indicating weak top-line momentum. Operating margin of -152.2% and net margin of -133.4% reflect an unsustainable profitability profile.
What is DTIL's revenue and growth?
Precision Biosciences Inc. reported revenue of $34.3M.
Does DTIL pay dividends?
Precision Biosciences Inc. does not currently pay dividends.
Where can I find DTIL SEC filings?
Official SEC filings for Precision Biosciences Inc. (CIK: 0001357874) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DTIL's EPS?
Precision Biosciences Inc. has a diluted EPS of $-3.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DTIL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Precision Biosciences Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DTIL stock overvalued or undervalued?
Valuation metrics for DTIL: ROE of -49.6% (sector avg: 15%), net margin of -133.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DTIL stock in 2026?
Our dual AI analysis gives Precision Biosciences Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DTIL's free cash flow?
Precision Biosciences Inc.'s operating cash flow is $-65.8M, with capital expenditures of $85.0K. FCF margin is -192.4%.
How does DTIL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -133.4% (avg: 12%), ROE -49.6% (avg: 15%), current ratio 13.32 (avg: 2).